Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Non-Current Deffered Revenue (2020 - 2023)

Historic Non-Current Deffered Revenue for Molecular Partners Ag (MOLN) over the last 3 years, with Q4 2022 value amounting to $3.8 million.

  • Molecular Partners Ag's Non-Current Deffered Revenue fell 4973.11% to $3.8 million in Q4 2022 from the same period last year, while for Dec 2022 it was $3.8 million, marking a year-over-year decrease of 4973.11%. This contributed to the annual value of $3.8 million for FY2022, which is 4973.11% down from last year.
  • Per Molecular Partners Ag's latest filing, its Non-Current Deffered Revenue stood at $3.8 million for Q4 2022, which was down 4973.11% from $7.5 million recorded in Q4 2021.
  • Over the past 5 years, Molecular Partners Ag's Non-Current Deffered Revenue peaked at $7.5 million during Q4 2021, and registered a low of $3.3 million during Q4 2020.
  • Its 3-year average for Non-Current Deffered Revenue is $4.8 million, with a median of $3.8 million in 2022.
  • In the last 5 years, Molecular Partners Ag's Non-Current Deffered Revenue surged by 13101.19% in 2021 and then crashed by 4973.11% in 2022.
  • Molecular Partners Ag's Non-Current Deffered Revenue (Quarter) stood at $3.3 million in 2020, then skyrocketed by 131.01% to $7.5 million in 2021, then plummeted by 49.73% to $3.8 million in 2022.
  • Its Non-Current Deffered Revenue was $3.8 million in Q4 2022, compared to $7.5 million in Q4 2021 and $3.3 million in Q4 2020.